Avastin biosimilars making progress

17 November 2016

Biosimilars of top-selling biological drugs are coming closer to the market, and such competition to Swiss pharma major Roche’s (ROG: SIX) blockbuster cancer drug Avastin (bevacizumab) – with 2015 sales of 6.68 billion Swiss francs ($7.67 billion) - is no exception.

Yesterday, US biotech major Amgen (Nasdaq: AMGN) and Allergan (NYSE: AGN) announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration for ABP 215, a biosimilar candidate to Avastin. ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies believe this submission is the first bevacizumab biosimilar application submitted to the FDA.

"ABP 215 is one of four oncology biosimilars in our pipeline, and today's BLA submission is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean Harper, executive vice president of R&D at Amgen, adding: "ABP 215 has the potential to offer an additional high-quality therapeutic option for patients diagnosed with cancer, continuing Amgen's mission of providing patients with vital medicines."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK